Today marks the start of Melanoma Awareness Month, and it comes at a time of remarkable progress and excitement in the field of melanoma research. Eight new drugs have been approved for melanoma in five years, strengthening our ability to help those suffering with this disease.
Even with these exciting developments, the death rate for patients with advanced melanoma is still far too high. And rates of melanoma are continuing to rise, at a time when cancer rates overall have declined. Prevention and early detection remain the best strategy for improving outcomes for patients with melanoma.
MRA remains passionate about funding cutting-edge research around the world, improving understanding of the therapies that work best, and continuing to accelerate the development of treatment options for patients. Here are four ways you can help during Melanoma Awareness Month:
If you need more information or would like to talk about additional opportunities, please contact Logan Kastner, Director of Marketing and Development.
Thanks for your continued support in our fight against melanoma.
Acting President and CEO
UPDATES FROM MRA
AACR Meeting Highlights Developments in Melanoma Research
Investigators supported by the Melanoma Research Alliance (MRA) once again headlined sessions at this year’s annual meeting of the American Association for Cancer Research (AACR), held April 18-22 in Philadelphia. Read more.
Chief Science Officer Featured in AACR Leadership Newsletter
MRA’s Louise Perkins was interviewed for a feature in the AACR’s Women In Cancer Research newsletter. Read the interview.
MRA-Funded Research Suggests Immunotherapy Combined with Radiation May Represent a Promising Approach
Treating metastatic melanoma with immunotherapies that target the CTLA4 and PD-1 pathways and radiation therapy suggests that the combination boosts the immune system’s attack on the disease. The research, led by a multidisciplinary team of investigators from the University of Pennsylvania, including MRA Pilot Award recipient Ramesh Rengan (now at the University of Washington), was published in the journal Nature. Read more about this research.
Save the Date for Leveraged Finance Fights Melanoma
Join the biggest names in leveraged finance for an evening of networking on May 19 to benefit MRA. Join us.
MELANOMA RESEARCH ALLIANCE FOUNDATION (Melanoma Research Alliance; MRA) is a GuideStar Exchange Gold Participant Want to learn more about the GuideStar Exchange?
Click here »